Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Galceran

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Hipertension Y Riesgo Vascular|March 20, 2024
Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?J M Galceran
Hipertension Y Riesgo Vascular|July 31, 2017
[Potassium, the narrow strip between life and death]J M Galceran
Current Opinion in Cardiology|September 1, 1996
End-stage renal disease: why aren't improvements in hypertension treatment reducing the risk?E Jaimes, J M Galceran, L Raij
Kidney International|September 12, 1998
Angiotensin II induces superoxide anion production by mesangial cellsE A Jaimes, J M Galceran, L Raij
Hipertension Y Riesgo Vascular|March 21, 2024
Hypertension and Vascular Risk already has an impact factor. Now a new challenge beginsP Armario, E Vinyoles, T Gijon-Conde, et al.
Hipertension Y Riesgo Vascular|February 14, 2022
Hypertension and Vascular Risk: A New step forwardP Armario, E Vinyoles, J M Galceran, et al.
Nephron|January 1, 1995
Effect of ciclosporin on serum lipids and modification with LSL 90202, a lysine salt of eicosapentaenoic acidJ Torras, I Herrero, A Castells, et al.
Transplantation Proceedings|February 1, 1992
Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantationJ M Griñó, A M Castelao, D Serón, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 1, 1992
Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized studyJ M Grino, A M Castelao, D Serón, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Hipertension Y Riesgo Vascular|March 20, 2024
Is proteinuria an important fact concerning the nephroprotective effect of renin-angiotensin system inhibitors?J M Galceran
Hipertension Y Riesgo Vascular|July 31, 2017
[Potassium, the narrow strip between life and death]J M Galceran
Current Opinion in Cardiology|September 1, 1996
End-stage renal disease: why aren't improvements in hypertension treatment reducing the risk?E Jaimes, J M Galceran, L Raij
Kidney International|September 12, 1998
Angiotensin II induces superoxide anion production by mesangial cellsE A Jaimes, J M Galceran, L Raij
Hipertension Y Riesgo Vascular|March 21, 2024
Hypertension and Vascular Risk already has an impact factor. Now a new challenge beginsP Armario, E Vinyoles, T Gijon-Conde, et al.
Hipertension Y Riesgo Vascular|February 14, 2022
Hypertension and Vascular Risk: A New step forwardP Armario, E Vinyoles, J M Galceran, et al.
Nephron|January 1, 1995
Effect of ciclosporin on serum lipids and modification with LSL 90202, a lysine salt of eicosapentaenoic acidJ Torras, I Herrero, A Castells, et al.
Transplantation Proceedings|February 1, 1992
Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantationJ M Griñó, A M Castelao, D Serón, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 1, 1992
Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized studyJ M Grino, A M Castelao, D Serón, et al.
Pageof 1